Flerie

Flerie Forward P/E

The Forward P/E Ratio of Flerie (FLERIE.ST) as of Nov 5, 2026 is -3.54. In the previous year, Forward P/E Ratio was -11.74 — a change of -69.88% (higher).

Forward P/E

-3.54

YoY

-69.88%

Last updated:

Forward P/E Ratio of Flerie is 2025 -3.54 . Forward P/E Ratio of Flerie was 2024 -11.74 . It decreases by -69.88% higher compared to the previous year.

The Flerie Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-32.58 SEK
Jan 1, 2019
-30.49 SEK
Jan 1, 2020
-46.61 SEK
Jan 1, 2021
-25.97 SEK
Jan 1, 2022
-26.67 SEK
Jan 1, 2023
-28.09 SEK
Jan 1, 2024
-11.74 SEK
Jan 1, 2025
-3.54 SEK
The Flerie Forward P/E history
YEARForward P/EYoY
-3.54-69.88%
-11.74-58.22%
-28.09+5.32%
-26.67+2.70%
-25.97-44.28%
-46.61+52.87%
-30.49-6.41%
-32.58-11.43%
-36.78-43.27%
-64.84-27.61%
-89.56-50.24%
-179.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Flerie Stock analysis

What does Flerie do? InDex Pharmaceuticals Holding AB develops drugs for inflammation and cancer, including cobitolimod for ulcerative colitis. The company offers a diagnostic kit called DiBiCol, which uses PCR to monitor seven biomarkers from colonic biopsies for ulcerative colitis or Crohn’s disease. InDex Pharmaceuticals AB and InDex Diagnostics AB are its subsidiaries, with SEB Venture Capital, Industrifonden, and NeoMed Management as shareholders. The firm focuses on pharmaceutical development and immuno-modulatory sequences (DIMS) for immunological diseases. The company generates revenue through the development and commercialization of cobitolimod and DIMS-based platforms. DiBiCol diagnostic kits are sold to healthcare providers for monitoring ulcerative colitis and Crohn’s disease. SEB Venture Capital, Industrifonden, and NeoMed Management are key investors supporting the company's research and development activities. InDex Pharmaceuticals Holding AB operates as a parent company for its subsidiaries in pharmaceutical and diagnostic fields. Flerie is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Flerie stock

Forward P/E Ratio of Flerie is -3.54 in 2025.

Forward P/E Ratio of Flerie changed from -11.74 to -3.54, representing a -69.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Flerie since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Flerie with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Flerie

All Key Metrics — Flerie